Advice

following a resubmission:

patiromer (Veltassa®) is not recommended for use within NHSScotland.

Indication under review: for the treatment of hyperkalaemia in adults.

In a clinical study, patients with chronic kidney disease (CKD) and hyperkalaemia who were taking at least one renin angiotensin aldosterone system (RAAS) inhibitor, were treated with patiromer for four weeks. Patients who had responded to patiromer (with normalisation of serum potassium concentrations) were then randomised to either continue patiromer, or placebo. Patiromer treatment during this withdrawal phase was associated with a significant change in serum potassium concentrations after four weeks, when compared with placebo.

The submitting company did not present a sufficiently robust economic analysis to gain acceptance by SMC.

Medicine details

Medicine name:
patiromer (Veltassa)
SMC ID:
SMC2264
Indication:

For the treatment of hyperkalaemia in adults.

Pharmaceutical company
Vifor Pharma
BNF chapter
Nutrition and blood
Submission type
Resubmission
Status
Not recommended
Date advice published
09 November 2020